Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Look at Larry Robbins’ Take on the Pharma Industry and Four Picks He Is Bullish On

Page 1 of 2

Larry Robbins of Glenview Capital is one of the most widely-watched investors on Wall Street. During the nine year period from 2001 until 2010, Glenview managed to return over 300% by holding a diversified portfolio, but mainly focusing on healthcare. As Robbins recently outlined in a letter to investors, his bias towards healthcare is based on the fact that the sector has been consistently reporting earnings growth. However, during the third quarter, amid a broader market sell-off, many of Robbins’ healthcare picks lagged, though the investor attributes this underperformance to external factors rather than weak fundamentals of the companies in which he is invested. We have previously discussed some of Robbins’ picks from the hospital and managed care industry, which amassed the largest shares of Glenview’s healthcare allocation (see details). In this article, we will assess some of the fund’s picks from the pharmaceutical and other industries.


We follow Glenview among over 700 other hedge funds, because we believe that imitating hedge fund activity can generate market beating returns over the long-term. However, our backtests that covered the period between 1999 and 2012 showed that following hedge funds’ into their most popular picks generally slightly underperforms the market, while imitating their top small-cap ideas can produce returns well above the benchmark. Our strategy involves following the 15 most popular small-cap picks among hedge funds and it has returned 102% since August 2012, beating the market by some 53 percentage points (see more details here).

Larry Robbins
Larry Robbins
Glenview Capital

Among the external factors that affected Glenview’s returns are the recent issues involving Turing Pharmaceuticals, which raised the price of a drug to $750 from $13.50 shortly after acquiring the rights to it, which led to a lot of political talk regarding drug-pricing policies. However, Robbins assured his investors that all of his pharmaceutical picks generated earnings growth through volume growth and “responsible aggregate pricing decision.” Another factor involves Valeant Pharmaceuticals Intl Inc (NYSE:VRX), of which Glenview has never owned any shares, but, whose 60% drop since August negatively affected other industry names.

“We have no position in Valeant because, to the best of our current knowledge, they are guilty of what looks to be poor judgment in historical price increases on acquired products, but they do not appear to be a fraudulent enterprise, making its share price a gamble on sentiment rather than a long or short investment,” Robbins said.

It should be mentioned that other big players from the hedge fund industry are very bullish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), including Jeff Ubben and Bill Ackman.

Follow Valeant Pharmaceuticals International Inc. (NYSE:VRX)
Trade (NYSE:VRX) Now!

In its latest 13F, Glenview revealed AbbVie Inc (NYSE:ABBV) as its largest holding in the pharma industry, the fund holding 17.86 million shares at the end of June, which represented an increase of 15.41 million shares during the second quarter. AbbVie’s stock lost 18% during the third quarter and took another hit recently after a notice from the U.S Food and Drug Administration that stated AbbVie Inc (NYSE:ABBV)’s Hep-C drug had a high chance of causing liver failure. However, Robbins remains bullish on AbbVie Inc (NYSE:ABBV) over the long-term, and said in the letter that the Hep-C drug problem does not affect Glenview’s long-term thesis, “even under the worst case scenario, which would involve zero future sales of their current Hep-C compound.”

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

On the following page we will discuss one more pharmaceutical stock that Robbins is bullish on, namely Allergan PLC (NYSE:AGN). We will also see why Glenview cut its stake in the pet care company VCA Inc (NASDAQ:WOOFearlier in August.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!